A Clear Line of Sight to Commercial Success
Aging global populations, rising rates of diabetes and hypertension, and increasing incidence of autoimmune diseases that affect eye health are all contributing to the growing need for novel therapies that more effectively treat ocular diseases. Your compound is racing to be among them.
PPD’s team of dedicated ophthalmological professionals can quickly determine the market potential for your ophthalmic drug or device using our full suite of innovative end-to-end drug development and study design capabilities. Our experts navigate complex worldwide trials with an expansive network of experienced ophthalmic research sites and professionals, while offering patient services that improve patient recruitment and increase retention.
Ophthalmic Product Experts Can Drive your Ocular Disease Therapy’s Development
On your way to commercialization, we enable you find the clearest path for your eye disease therapy that avoids unnecessary delays in the drug development process with proactive expertise optimizing your study’s design from the very start.
Whether you are researching neurological disorders that affect the eye or systemic neurological diseases with ocular manifestations as the result of the deterioration of the brain, such as Parkinson’s and Alzheimer’s diseases, PPD has a dedicated global team with extensive experience in conducting ocular clinical trials.
Our ophthalmological team is backed by approximately 300 clinical professions and supported by three board-certified ophthalmologists with over 40 combined years of clinical drug and medical device experience, including within the U.S. Food and Drug Administration (FDA).
When you need end-to-end strategic guidance, safety oversight, team training, and expert consulting on protocol and regulatory strategy development, PPD’s experts are here to help. They also have experience with:
- Accessing our international network of experienced investigators for historical data
- Data management and biostatistics
- Managing equipment needs
- Quality oversight
The Past 5 Years of PPD’s Ophthalmology Experience
Ophthalmology Clinical Studies
Experienced Global Sites
Dedicated Ophthalmological Professionals Worldwide
Experience Developing Drugs for Many Types of Eye Disorders
Advance your ophthalmic research with PPD’s expertise. Our ophthalmological experience is vast, addressing chronic, acute and rare eye diseases in both adult and pediatric populations. The types of eye disorders that PPD has worked on include:
- Acute optic neuritis
- Age-related macular degeneration
- Corneal wound healing
- Diabetic macular edema/diabetic retinopathy
- Dry eye
- Geographic atrophy
- Glaucoma/ocular hypertension
- Leber’s congenital amaurosis
- Lens opacification/post-cataract surgical inflammation
- Myopia and Fuchs dystrophy
- Retinal vein occlusion
- Retinopathy of prematurity
- Retinitis pigmentosa
- Usher syndrome
To drive your project forward, we assign key functional lead experts who have deep ophthalmic research experience spanning early development, patient-reported outcomes, Phase I-IV trials, observational research, real-world evidence of market value and more.
We’ve formed strategic partnerships with top-performing ophthalmology sites globally, offering you access to our network of more than 2,000 global investigators. Our Rare Disease and Pediatric Center of Excellence focuses on rare and pediatric diseases in particular and features extensive cross-functional expertise in eye disorders.
End-to-end Ocular Drug Development Capabilities
A Sampling of Our Successes
PPD has demonstrated successes on a variety of ocular projects. Some of our achievements include:
- Reduced global site activation timelines by more than 30% through the use of innovative site feasibility and activation strategies
- Accelerated site startup by 30 days using PPD-selected sites and leveraging our preferred site relationships
- Boosted enrollment by 25% on a dry eye study and beat enrollment timelines by a month on an age-related macular degeneration (AMD) treatment-naïve trial by employing proactive enrollment strategies
- Facilitated registration approval for products to treat AMD, branch retinal vein occlusion, central retinal vein occlusion, uveitis and diabetic macular edema
We have experience with more than seven central reading vendors in:
As you focus on your ophthalmology development projects, PPD is here to help. Connect with us to learn more about our experienced team.